Geranylgeranyl diphosphate synthase (GGPS); increases the intracellular pool of geranylgeranyl diphosphate, suppressor of bet2 mutation that causes defective geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Geranylgeranyl diphosphate synthase (GGPS); increases the intracellular pool of geranylgeranyl diphosphate, suppressor of bet2 mutation that causes defective geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Geranylgeranyl diphosphate synthase (GGPS); increases the intracellular pool of geranylgeranyl diphosphate, suppressor of bet2 mutation that causes defective geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic.

Farnesyl pyrophosphate synthetase; has both dimethylallyltranstransferase and geranyltranstransferase activities; catalyzes the formation of C15 farnesyl pyrophosphate units for isoprenoid and sterol biosynthesis.

Geranylgeranyl diphosphate synthase (GGPS); increases the intracellular pool of geranylgeranyl diphosphate, suppressor of bet2 mutation that causes defective geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic.

Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Geranylgeranyl diphosphate synthase (GGPS); increases the intracellular pool of geranylgeranyl diphosphate, suppressor of bet2 mutation that causes defective geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Farnesyl pyrophosphate synthetase; has both dimethylallyltranstransferase and geranyltranstransferase activities; catalyzes the formation of C15 farnesyl pyrophosphate units for isoprenoid and sterol biosynthesis.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

C-24(28) sterol reductase; catalyzes the final step in ergosterol biosynthesis; mutants are viable, but lack ergosterol; Belongs to the ERG4/ERG24 family.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Very-long-chain 3-oxoacyl-CoA reductase; Microsomal beta-keto-reductase; contains oleate response element (ORE) sequence in the promoter region; mutants exhibit reduced VLCFA synthesis, accumulate high levels of dihydrosphingosine, phytosphingosine and medium-chain ceramides; Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Geranylgeranyl diphosphate synthase (GGPS); increases the intracellular pool of geranylgeranyl diphosphate, suppressor of bet2 mutation that causes defective geranylgeranylation of small GTP-binding proteins that mediate vesicular traffic.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Farnesyl pyrophosphate synthetase; has both dimethylallyltranstransferase and geranyltranstransferase activities; catalyzes the formation of C15 farnesyl pyrophosphate units for isoprenoid and sterol biosynthesis.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

C-24(28) sterol reductase; catalyzes the final step in ergosterol biosynthesis; mutants are viable, but lack ergosterol; Belongs to the ERG4/ERG24 family.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway.

Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation.

Very-long-chain 3-oxoacyl-CoA reductase; Microsomal beta-keto-reductase; contains oleate response element (ORE) sequence in the promoter region; mutants exhibit reduced VLCFA synthesis, accumulate high levels of dihydrosphingosine, phytosphingosine and medium-chain ceramides; Belongs to the short-chain dehydrogenases/reductases (SDR) family.